Results 31 to 40 of about 1,534 (92)

Aceruloplasminemia Presenting With Prominent Psychiatric Symptoms and Neurodegeneration: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Aceruloplasminemia (ACP) often presents with systemic, psychiatric, and neurological features. In this case, diabetes mellitus was diagnosed several years before psychiatric symptoms, which were then followed by neurological decline, which significantly delayed diagnosis.
Ali Almarzooqi, Abdulrahman Almarzooqi, Khalifa Juma, Hamda Kamalboor   +3 more
wiley   +1 more source

Deferiprone, an Iron Chelator, is Preventive and Therapeutic in Experimental Crescentic Glomerulonephritis

, 2017
Crescentic glomerulonephritis represents the most severe form of antibody-mediated glomerulonephritis. It is an important cause of renal dysfunction worldwide and there is a need for more effective treatment.
Tai-Di Chen, Jeong-Hun Ko, H. Terence Cook, Jacques Behmoaras, Charles D. Pusey, Maria Prendecki, Stephen P. McAdoo   +6 more
core   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine

, 2018
We prospectively assessed the efficacy of deferasirox versus deferiprone or desferrioxamine as monotherapy in thalassaemia major (TM) patients by magnetic resonance imaging (MRI).
D'Ascola D. G., Restaino G., Meloni A., Lisi R., Mangione M., Pepe A., Cuccia L., Pistoia L., Gamberini M. R., Ricchi P., Righi R., Rosso R., Allo M., Positano V., Spasiano A.   +14 more
core   +1 more source

Deferiprone attenuates neuropathology and improves outcome following traumatic brain injury

, 2023
BACKGROUND AND PURPOSE: Traumatic brain injury (TBI) remains a leading cause of mortality and morbidity in young adults. The role of iron in potentiating neurodegeneration following TBI has gained recent interest as iron deposition has been detected in ...
Rao, SS, Miles, LQ, Juan, SMA, Adlard, PA, Truong, PH, Daglas, M   +5 more
core   +1 more source

Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. [PDF]

, 2008
Background: Cardiac iron overload is the leading cause of death in thalassemia major and is usually assessed using myocardial T2* measurements. Recently a cardiovascular magnetic resonance (CMR) breath-hold T2 sequence has been developed as a possible ...
Tan, RS, Tan Ru, Chan, G.C.F, He, T, Fogel Mark A, Firmin David N, Au, W-Y, Pennell, Dudley J., Chan, GCF, Fogel, MA, Lam, W.M, Aydinok, Y, Chu, WCW, He, Taigang, Cohen, AR, Ng, I, Chu Winnie CW, Cohen, Alan R., Pennell, DJ, Pennell Dudley J, Firmin, D.N, Chu, W.C.W, Biceroglu, S, Fogel, M.A, Tan, R.S, Lam, WM, Chan Godfrey CF, Lam Wynnie M, Firmin, David N., Biceroglu Selen, Aydinok Yesim, Aydinok, Yesim, Firmin, DN, Kirk, Paul, Fogel, Mark A., Pennell, D.J, Ng Ivy, Kirk, P, Au, Wing-Yan, Tan, Ru San, Au, WY, He Taigang, Kirk Paul, Chan, GC, Biceroglu, Selen, Cohen, A.R, Au Wing-Yan, Chu, Winnie C. W., Chu, WC, Au, W.-Y, Lam, Wynnie M., Cohen Alan R, Ng, Ivy, Chan, Godfrey C. F.   +53 more
core   +1 more source

Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis [PDF]

, 2019
OBJECTIVE: Deferiprone is an iron chelator that has recently been used to treat patients with infratentorial superficial siderosis (iSS). It is considered to have a generally favourable safety profile but concerns have been raised due to the risk of ...
Cowley, P, Sammaraiee, Y, Eleftheriou, P, Hylton, B, Porter, J, Banerjee, G, Werring, DJ, Farmer, S   +7 more
core   +1 more source

Deferiprone increases endothelial nitric oxide synthase phosphorylation and nitric oxide production

, 2018
Iron chelation can improve endothelial function. However, effect on endothelial function of deferiprone has not been reported. We hypothesized deferiprone could promote nitric oxide (NO) production in endothelial cells.
Rattanawonsakul , Krit, Vivithanaporn, Pornpun, Thanaporn Sriwantana, Nathawut Sibmooh, Sibmooh, Nathawut, Sirada Srihirun, Pornpun Vivithanaporn, Krit Rattanawonsakul, Paiboonsukwong, Kittiphong, Sriwantana, Thanaporn, Kittiphong Paiboonsukwong, Srihirun, Sirada   +11 more
core   +1 more source

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients [PDF]

, 2015
Background: Iron overload is a predictable and lifethreatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major.
Haniye Mohsenkhah Amlashi, Amlashi, H.M., Nargesbeygom Mirbehbahani, Mirbehbahani, N., Jahazi, A., Behnampour, N., Azam Jahazi, Naser Behnampour   +7 more
core   +1 more source

ALT elevations correlating with deferiprone chelation.

, 2019
(A) Patient #34, (B) Patient #1, (C) Patient #19 (datafile). Normal ALT
Brenda L. Gallie (249953), Nancy F. Olivieri (6407168), Amir Sabouhanian (6407171)   +2 more
core   +1 more source